New offering will expand access to powerful analytical platforms
21 March, 2013
The European Commission (EC) has approved expanded options for pre-treatment prior to use of QUTENZA (8% capsaicin patch). Before application the patient may now take an oral analgesic, or the treatment area may be pre-treated with a topical anaesthetic.1 The 8% capsaicin patch is the first and only licensed high concentration (8%) capsaicin cutaneous patch for the treatment of peripheral neuropathic pain in Europe.
14 March, 2013
The Government is preparing to take action to attract drug research projects back to the UK by ensuring that patent laws are consistent with those in most other EU member states, according to Withers & Rogers – one of the UK’s leading firms of patent and trade mark attorneys.
12 March, 2013
An innovative nasal spray that has been proven clinically effective against respiratory viruses has now been authorized for the Canadian market. The product, which was developed by the Viennese biotech company Marinomed, reduces the reproduction and spread of viruses on the nasal mucosa and is based on Marinomed's proprietary technology platform Mavirex®. Based on the expected market success of the nasal spray, one major international pharmaceutical concern has already decided to market the product in the fall.
06 March, 2013